Investment Thesis
Guardian Pharmacy Services demonstrates fundamental deterioration despite 17.9% revenue growth, with net income growth of only 0.5% YoY indicating margin compression. Most critically, the company generated negative free cash flow of -$7.4M despite $13.3M net income, revealing the business is not converting earnings to cash and is unsustainable at current capital requirements.
Strengths
- Strong revenue growth of 17.9% YoY demonstrates market expansion
- Zero long-term debt provides financial flexibility and eliminates interest burden
- Adequate liquidity with current ratio of 1.46x and $64.9M cash reserves
Risks
- Negative free cash flow of -$7.4M despite profitability signals unsustainable business model with cash burn
- Net income growth of 0.5% YoY versus 17.9% revenue growth indicates significant margin compression and deteriorating profitability
- Critically low profitability metrics (3.9% net margin, 5.3% operating margin) with weak capital returns (ROE 5.7%, ROA 3.1%) suggest structural challenges in the pharmacy retail sector
Key Metrics to Watch
- Free Cash Flow trajectory - must turn positive to validate business sustainability
- Operating Margin trend - currently at 5.3%, requires improvement to justify scale of operations
- Capital Expenditure as % of revenue - capex at 4.0% of revenue exceeded operating cash flow, need to validate ROI on capital deployment
Financial Metrics
Revenue
336.6M
Net Income
13.3M
EPS (Diluted)
$0.00
Free Cash Flow
-7.4M
Total Assets
426.9M
Cash
64.9M
Profitability Ratios
Gross Margin
22.7%
Operating Margin
5.3%
Net Margin
3.9%
ROE
5.7%
ROA
3.1%
FCF Margin
-2.2%
Balance Sheet & Liquidity
Current Ratio
1.46x
Quick Ratio
1.17x
Debt/Equity
0.00x
Debt/Assets
45.6%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T10:27:32.943622 |
Data as of: 2026-03-31 |
Powered by Claude AI